Foghorn TherapeuticsvsMerck & Company

FHTX and MRK stock compared: price, dividend, valuation and results, from SEC filings.

FHTX

Foghorn Therapeutics Inc.

$2.02

Value $118M

-2.17%
FHTX's page

MRK

Merck & Company, Inc.

$148.94

Value $368B

+0.79%
MRK's page

Foghorn Therapeutics (FHTX) has a market value of $118M and Merck & Company (MRK) $368B. Over the last year, with dividends, FHTX moved -56.7% and MRK +65.0%. The P/E is 20.7 for FHTX and 150.1 for MRK. Dividend yield: FHTX none, MRK 2.28%.

At a glance

The main figures of both. A bar only shows which number is larger, not which is better.

  • Market value

    FHTX$118M

    MRK$368B

    MRK is 3,113 times FHTX

  • Revenue, 12 months

    FHTX$112M

    MRK$67.4B

    MRK is 601 times FHTX

  • Net income, 12 months

    FHTX$9.4M

    MRK$2.5B

    MRK is 260 times FHTX

  • Operating margin

    FHTX2.1%

    MRK–

  • ROIC

    FHTX–

    MRK3.9%

  • P/E

    FHTX20.7

    MRK150.1

    MRK is 7.3 times FHTX

  • Dividend yield

    FHTX0.0%

    MRK2.3%

    2.3 points apart

  • 5-year return

    FHTX-85.1%

    MRK+107.3%

    192.4 points apart

A fainter bar means a negative number. The 5-year return includes dividends.

The price over time

Both start at 100 at the beginning of the period, so the lines show how much each changed. With dividends means each dividend buys more shares.

FHTX-85.1%

MRK+107.3%

10020020222023202420252026
Returns by period
PeriodFHTXWith dividendsMRKWith dividends
1 year since November 14, 2025-56.7%Price -56.7%+65.0%Price +60.3%
3 years since November 16, 2023-46.3%-18.7% a yearPrice -46.3%+60.0%+17.0% a yearPrice +46.0%
5 years since November 15, 2021-85.1%-31.7% a yearPrice -85.1%+107.3%+15.7% a yearPrice +78.0%

Each cell: the total return with dividends, its yearly rate, and the price change alone. Before taxes and costs. Past returns do not predict future ones.

Every figure

As on each company's page. A description, not a recommendation: no one figure says which is better.

FHTXFoghorn TherapeuticsMRKMerck & Company

Valuation

FHTXMRK
Valuation
Price$2.02$148.94
Market value$118M$368B
Enterprise value (EV)$38M$412B
P/E20.7150.1
P/E, 5-year median–14.8
P/B–8.2
EV/EBIT15.986.6
Free cash flow yield–4.0%

Results and growth

FHTXMRK
Results and growth
Revenue, 12 months$112M$67.4B
Net income, 12 months$9.4M$2.5B
Free cash flow, 12 months-$84M$14.7B
Earnings per share, 12 months$0.10$0.98
Revenue growth, year on year36.8%1.3%
Revenue growth a year, past+135.1%over 5 years+9.4%over 5 years
EPS growth a year, past–+21.2%over 5 years

Margins and returns on capital

FHTXMRK
Margins and returns on capital
Gross margin–71.8%
Operating margin2.1%–
Net margin8.4%3.6%
ROIC–3.9%
ROE–5.2%

Balance sheet

FHTXMRK
Balance sheet
Cash$80M$9.7B
Total debt$44M$53.8B
Net debt / EBITDA-14.15.7
Interest cover–2.4×

Dividends and buybacks

FHTXMRK
Dividends and buybacks
Dividend yield–2.3%
Dividend per share, 12 months–$3.40
Dividend growth a year, past–+5.8%over 5 years
Buyback yield–1.4%
Shareholder yield–3.7%

Last 12 months from the latest 10-Q and 10-K. Value, P/E and yields at today's price. A dash means the figure does not exist or did not pass our checks.

Questions: FHTX or MRK

Didn't find what you were looking for?

Ask us
Which is bigger, Foghorn Therapeutics or Merck & Company?

By market value, Merck & Company ($368B) is about 3,113.2 times Foghorn Therapeutics ($118M), at today's prices.

How did FHTX and MRK stock do over the last 5 years?

Since November 15, 2021, FHTX's price moved -85.1% and MRK's +78.0%. With dividends: FHTX -85.1% (-31.7% a year), MRK +107.3% (+15.7% a year). Past returns do not predict future ones.

Which pays the higher dividend, FHTX or MRK?

The dividend yield at today's price is none for Foghorn Therapeutics and 2.28% for Merck & Company. Over the last twelve months they paid – and $3.40 per share.

What is the P/E of FHTX and MRK?

At today's price, the P/E is 20.7 for FHTX and 150.1 for MRK. It is the share price over the last twelve months' earnings per share.

Which has the higher profit margins, Foghorn Therapeutics or Merck & Company?

Over the last twelve months, the net margin was 8.4% for Foghorn Therapeutics and 3.6% for Merck & Company, and the operating margin 2.1% and –. Revenue was $112M and $67.4B.

Which is the better investment, Foghorn Therapeutics or Merck & Company?

The page does not answer that and does not suggest buying or selling. It puts the two companies' numbers side by side, from their SEC filings, for you to read and form your own view. The decision depends on your goals and situation.

Other comparisons

With each of the two, and with the largest in its sector.

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

Descriptive data from SEC filings and market prices.